Compare BGH & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGH | BDSX |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.9M | 276.2M |
| IPO Year | 2011 | 2020 |
| Metric | BGH | BDSX |
|---|---|---|
| Price | $12.64 | $10.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.60 |
| AVG Volume (30 Days) | 122.6K | ★ 227.2K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $26.35 |
| Revenue Next Year | N/A | $20.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $12.37 | $5.26 |
| 52 Week High | $15.35 | $31.97 |
| Indicator | BGH | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 24.77 |
| Support Level | $12.37 | N/A |
| Resistance Level | $12.86 | $11.57 |
| Average True Range (ATR) | 0.16 | 2.25 |
| MACD | 0.04 | -1.34 |
| Stochastic Oscillator | 51.43 | 14.95 |
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation. The Fund seeks capital appreciation as a secondary investment objective when consistent with its primary investment objective. Under normal market conditions, the Fund will invest at least 80% of its Managed Assets in bonds, loans and other income-producing instruments that are, at the time of purchase, rated below investment grade.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.